RESEARCH-USE BIOSIMILAR ANTIBODY
Fiztasovimab
Monoclonal antibody · IgG1
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
TARGETHHV gB AD-1
YMonoclonal antibody
CATALOGSC-BS-539
CATALOG NUMBERSC-BS-539
MOLECULAR WEIGHTApprox. 144.49 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
Fiztasovimab is a recombinant research-use antibody directed against HHV gB AD-1.